.jpg)
San Francisco: Malaria is still the leading disease killer worldwide. In this regard, human trials of antibody therapy were initiated. Thus, the very promising results of the Phaseon human trial have come out.
According to the published results, scientists created an anti-malarial antibody and administered it to volunteers like a vaccine. All healthy individuals were then deliberately placed in a malarial environment with the aim of causing them to develop malaria. Amazingly, not a single volunteer contracted malaria.
Malaria-fighting proteins are strengthened thanks to the injection of antibodies called L-nine LS. But the time of effectiveness of antibodies is very less than that of vaccines and the effects gradually wear off in the body. Even effective only for a few weeks or months.
Two to six weeks after being inoculated with the antibodies, all participants were bitten by malaria mosquitoes, and two of the 17 people became ill. One of them was given the lowest dose by injection into a vein and the other was given a needle in the skin.
These are very encouraging results that demonstrate the utility of next-generation L-nine LS monoclonal antibodies. This will protect children especially from deadly malaria. It is believed that if a child under the age of five is given a single shot, he will be protected against malaria for the next six months.
Although their duration is shorter than that of vaccines, it should be noted that last year, a lot of claims were made about a malaria vaccine, 'Mosquirx', but the initial trial has proved to be a failure. This is why antibodies can provide protection against malaria, albeit with short-term efficacy.
